FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 33314 APPLICATION NO.

APPLICANT
WINDISCH ET AL
FILING DATE
FEBRUARY 13, 2006

Group

JUL 0 5 2006 85

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/ML/	AA	5,710,027	1/20/98	Hauptmann et, al			
	AB	2003/0026805	2/6/03	Athwal et,al.			
	AC	5,648,237	7/15/97	Paul J. Carter			
	AD	4,680,262	7/14/87	Bochner et, al.			
V	AE	2004/151695	8/5/04	Kwon et al.			
	AF						
	AG						
	АН						
	Al						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE .	CLASS	SUBCLASS	TRAN YES	SLATION NO
/ML/	AM	WO 89/00201	1/12/89	University of Dundee				
	AN	WO 03/004599	1/16/03	Insight strategy & Mkt Ltd				
	AO	EP 0 974 654	1/26/00	Mitsui Chemicals Inc				
1	AP	WO 01/57217	8/9/01	Choi Ki Doo et al.				
	AQ							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/ML/	AR	BOURDINEAUD J P ET AL: "Cytoplasn Ferredoxin in Escherichia-coli", Biochim	nic and Periplasmic Expression of a Synthetic gene for nie (Paris), vil.72, no. 6-7, 1990, pages 407-415, XP002316190		
	AS	WEICKERT M J ET, AL: "Optimization of Current opinion in Biotechnology. London	of Heterologous Protein Production in Escherichia Coli", on, GB, Vol. 7, no. 5, 1996, pages 494-499, XP000995157		
V	AT	HUMPHREYS D P ET AL: "High- LEVEL Periplasmic Expression in Escherichia coli Using a Eukaryotic Signal Peptide: Importance of Codon usage at the 5' end of the coding sequence" Protein expression and purification academic press, San Diego, CA, US, Vol. 20, no.2, November 2000, pgs			
EXAMINER		/Maria Leavitt/	DATE CONSIDERED 11/27/2007		

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO. 33314 APPLICATION NO.

(Use several sheets if necessary)

APPLICANT WINDISCH ET AL. FILING DATE **FEBRUARY 13, 2006**

Group

JUL U 5 2006

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

JEMIN					
/ML/ DA	Carboxybutanamidocephalosporanic- Bateriology, vol. 163, no. 3, 1985, pag				
DB	from the escherichia coli periplasm" E 19, no. 5, 1996, pages 332-338, XP0				
DC	fluids" Journal of Chromotography A, pages 199-210, XP004096275	combinant human growth hormone directly in osmotic shick , Elsevier Science, NL., Vol.s 782, no. 2, 10 October 1997,			
DD		n technologies for monoclonal antibodies and their fragments", I 15, No. 5, October 2004, Pages 456-462			
DE	DE OLIVEIRA J E ET AL: "High-yeild purification of biosynthetic human growth hormone secreted in Escherichia coli periplasmic space" Journal of Chromatogrpahy A, Elsevier Science, NL. Vol. 852, no.2 13, Aug 1999, pgs 441-450				
. DF	HANNIG G ET AL:" Strategies for optimizing heterologous protein expression in Escherichia coli", Trends in Biotechnology, Vol. 16, no. 2., February 1998, pages 54-60, XP004107042				
DG	MIDDLEBERG A P J: "Process-scale disruption of microorganisms" Biotechnology Advances, Vol. 13, no.3 1995, pages 491-551, XP004045404				
DH	BANEYX F: Recombinant protein exp vol 10, no. 5, October 1999, pgs 411-	oression in Escherichia coli" current opinion in Biotechnology, 421, XP001041299			
DI	HART R A ET AL: "Large scale, in situ isolation of periplasmic IGF-I from E. Coli", Bio Technolog Vol. 12, November 1994, pages 1113-1117, XP001153305				
. D1					
DK					
DL					
DM					
DN					
EXAMINER	/Maria Leavitt/	DATE CONSIDERED 11/27/2007			

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.